RxDoctor Payments Data

Mark Schultz, MD

Family Medicine · Springfield, MONPI 1265477517

Payments from drug & device makers

$11,024in general payments, 2019–2025

Across 757 payments — averaging $14.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Pfizer$1K
  • Lilly USA, LLC$1K
  • GSK$920
  • AbbVie$906
  • Boehringer Ingelheim$848
  • plus $5K from 38 others

What the payments were for

  • Food & beverage$10,94199%
  • Education$831%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,024 in reported general payments places this provider in the 95th percentile of 2,203 family medicine providers in Missouri.

See all family medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$36,970
Medicare patients
183
Services billed
441

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban204$152,689
JardianceEmpagliflozin106$99,013
MounjaroTirzepatide70$77,488
RybelsusSemaglutide69$76,008
OzempicSemaglutide63$75,470
FarxigaDapagliflozin Propanediol81$52,526
Trelegy ElliptaFluticasone/Umeclidin/Vilanter56$41,921
XareltoRivaroxaban44$33,192
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog36$32,636
Tresiba Flextouch U-200Insulin Degludec23$25,951
TrulicityDulaglutide19$24,134
TradjentaLinagliptin35$23,991
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$11,277
MyrbetriqMirabegron11$7,630
Janumet XrSitagliptin Phos/Metformin Hcl13$6,869

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,068$152,689204 claims
Novo NordiskRybelsus, Ozempic$696$151,477132 claims
Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat$848$129,530154 claims
Lilly USA, LLCMounjaro, Trulicity$1,006$101,62289 claims
AstraZenecaFarxiga$1,098$52,52681 claims
GSKTrelegy Ellipta, Arexvy$920$45,54869 claims
Johnson & JohnsonXarelto$293$33,19244 claims
Astellas Pharma US IncMyrbetriq$213$7,63011 claims
MerckJanumet Xr$133$6,86913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,203 family medicine providers in Missouri.

Other family medicine in Springfield

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →